Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates

Core Insights - Rigel Pharmaceuticals (RIGL) reported quarterly earnings of $1.46 per share, exceeding the Zacks Consensus Estimate of $0.93 per share, and showing an increase from $0.7 per share a year ago, resulting in an earnings surprise of +56.99% [1] - The company achieved revenues of $69.46 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 12.80% and up from $55.31 million year-over-year [2] - Rigel's stock has increased by approximately 82.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 16.5% [3] Earnings Outlook - The future performance of Rigel's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook, including current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is $0.87 on revenues of $64.23 million, and for the current fiscal year, it is $5.49 on revenues of $280.85 million [7] Industry Context - The Medical - Drugs industry, to which Rigel belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of Rigel's stock may also be influenced by the overall industry outlook, as empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]